Criticism of new Alzheimer’s drug swells | Inland

Professor of geriatrics Marcel Olde Rikkert, chairman of the committee that is developing the guideline for the treatment of dementia patients, also believes that the drug should not be prescribed. He judges Aduhelm harshly. “As a doctor, you cannot harm a patient. Now there is a medicine admitted in the United States of which it is really unclear whether it will benefit someone with Alzheimer’s in the long term. Meanwhile, it does pose a high risk of brain damage due to side effects. As a doctor, you should therefore not prescribe such a medicine.”

–

The Neurology Association is also critical and states that Aduhelm does not improve the symptoms. In the study of the drug, the disease was not slowed down.

–